Research shows that a protein called NAT10 significantly accelerates aortic valve calcification by modifying the PCSK9 gene, and blocking NAT10 in mice substantially reduced valve hardening. According to Gram Research analysis, NAT10 levels were substantially higher in calcified valves from human patients and mice with the disease, and when researchers blocked NAT10 using two different methods, valve calcification decreased significantly in treated mice compared to untreated controls.

Researchers discovered that a protein called NAT10 plays a major role in causing aortic valve calcification, a condition where the heart valve hardens and stops working properly. Using Gram Research analysis of human tissue and mouse studies, scientists found that NAT10 activates another protein called PCSK9, which triggers the valve cells to become bone-like. When they blocked NAT10 in mice with high cholesterol, the valve hardening slowed down significantly. This discovery opens new doors for treating calcific aortic valve disease, a serious condition affecting millions of people worldwide, by targeting this newly identified protein pathway.

Key Statistics

A 2026 study published in iScience found that NAT10 expression was significantly elevated in calcified aortic valves from both human patients and mice, with higher NAT10 levels correlating with increased disease severity in human tissue samples.

Pharmacological NAT10 inhibition using remodelin and targeted protein degradation using PROTAC NP1192 both substantially reduced aortic valve calcification in high-cholesterol diet-fed mice compared to untreated controls.

Research identified that NAT10 catalyzes ac4C modification of PCSK9 messenger RNA, enhancing transcript stability and increasing pro-calcific protein production in human valve cells.

In laboratory studies, blocking NAT10 activity reduced human valvular interstitial cells’ tendency to undergo osteogenic differentiation, the bone-like transformation that characterizes valve calcification.

The Quick Take

  • What they studied: How a protein called NAT10 causes aortic valve calcification, the hardening of the heart valve that makes it difficult for blood to flow properly.
  • Who participated: The research used human valve tissue samples from patients with calcified valves, laboratory-grown human valve cells, and genetically modified mice fed a high-cholesterol diet to mimic the disease.
  • Key finding: NAT10 levels were significantly higher in calcified valves from both patients and mice. When researchers blocked NAT10 using two different methods, valve hardening decreased substantially in the mice.
  • What it means for you: This research identifies a new target for treating aortic valve calcification, potentially leading to medications that could slow or prevent this serious heart condition. However, these findings are still in early stages and human clinical trials are needed before any new treatments become available.

The Research Details

This research combined multiple approaches to understand how NAT10 causes valve hardening. First, scientists examined valve tissue from patients with calcified valves and compared it to healthy valves, finding that NAT10 levels were much higher in the diseased tissue. They also grew human valve cells in the laboratory and exposed them to conditions that trigger calcification, observing how NAT10 influenced this process.

The team then used genetically modified mice that naturally develop valve calcification when fed a high-cholesterol diet. They tested two different methods to reduce NAT10 activity: one using a drug called remodelin and another using a newer technique called PROTAC NP1192 that causes the NAT10 protein to be destroyed. By measuring valve calcification in these treated mice, they could determine whether blocking NAT10 actually prevented the disease.

Finally, researchers investigated the molecular mechanism by identifying which genes NAT10 controls. They discovered that NAT10 modifies the PCSK9 gene’s messenger RNA, making it more stable and allowing more PCSK9 protein to be produced, which then triggers valve cells to calcify.

Understanding the exact mechanism of valve calcification is crucial because current treatments are limited. By identifying NAT10 as a key player, researchers can now develop targeted therapies that specifically block this protein rather than using broad approaches that might have side effects. This research also reveals that a process called ac4C acetylation, which was previously unknown to play a role in valve disease, is actually central to the problem.

The study demonstrates strong quality through multiple lines of evidence. The findings were consistent across human tissue samples, laboratory cell cultures, and living animal models, which increases confidence in the results. The use of two different methods to block NAT10 (pharmacological inhibition and protein degradation) and the identification of the specific molecular pathway (NAT10-ac4C-PCSK9) provide mechanistic support for the conclusions. Publication in iScience, a peer-reviewed scientific journal, indicates the work met rigorous scientific standards. However, the research was conducted in mice and laboratory settings, so results may not directly translate to humans without further testing.

What the Results Show

The research revealed that NAT10 protein and ac4C modification levels are substantially elevated in calcified aortic valves from both human patients and mice with the disease. In human valve tissue samples, patients with more severe calcification showed higher NAT10 expression, suggesting a direct relationship between NAT10 levels and disease severity.

When researchers exposed human valve cells to calcification-promoting conditions in the laboratory, NAT10 activity increased, and blocking NAT10 reduced the cells’ tendency to become bone-like. This demonstrated that NAT10 actively drives the calcification process at the cellular level.

In mice fed a high-cholesterol diet, both methods of reducing NAT10 (using the drug remodelin and the protein degradation technique PROTAC NP1192) significantly reduced valve calcification compared to untreated mice. This showed that blocking NAT10 could actually prevent or slow the disease in living animals.

The mechanistic discovery was equally important: NAT10 modifies the PCSK9 gene’s messenger RNA through ac4C acetylation, which stabilizes the message and allows more PCSK9 protein to be made. PCSK9 then acts as a pro-calcific factor, triggering the cascade that hardens the valve.

The research demonstrated that the NAT10-ac4C-PCSK9 pathway represents a previously unknown regulatory mechanism in valve disease. The finding that ac4C modification, an epitranscriptomic process (a way that cells modify RNA without changing the genetic code), plays a role in aortic valve calcification opens new research directions. The correlation between NAT10 expression levels and disease severity in human patients suggests that measuring NAT10 levels might eventually help doctors assess how advanced a patient’s valve disease is.

Previous research identified various factors contributing to aortic valve calcification, including cholesterol accumulation, inflammation, and bone-forming processes. This study adds a new layer of understanding by identifying the specific molecular switch (NAT10 and ac4C modification) that activates these processes. While earlier studies showed that PCSK9 is involved in cardiovascular disease, this is the first research demonstrating that NAT10 controls PCSK9 through ac4C modification in the context of valve calcification. This represents a significant advance in understanding the disease mechanism.

The study was primarily conducted in mice and laboratory cell cultures, which may not perfectly replicate how the disease works in human hearts. The sample size of human tissue samples was not specified in the abstract, making it unclear how many patients were studied. The research used mice with genetic modifications and high-cholesterol diets, which may not fully represent the natural disease progression in humans. Additionally, while the study identified NAT10 as a therapeutic target, the actual development and testing of new medications in humans would require extensive additional research and clinical trials. The long-term effects of blocking NAT10 in humans are unknown.

The Bottom Line

Based on this research, blocking NAT10 appears to be a promising strategy for treating aortic valve calcification. However, these findings are preliminary and based on laboratory and animal studies. High confidence: NAT10 is a legitimate therapeutic target worth pursuing. Moderate confidence: Drugs that block NAT10 may eventually help patients with aortic valve calcification. Low confidence: Any specific medication is ready for human use at this time. Anyone with aortic valve disease should continue following their doctor’s current treatment recommendations while researchers develop new therapies based on these findings.

People with aortic valve calcification or those at risk for developing it (such as those with high cholesterol, high blood pressure, or chronic kidney disease) should be aware of this research as it may lead to new treatment options. Cardiologists and researchers studying heart valve disease should pay close attention to these findings. People without valve disease do not need to take action based on this research alone. Patients should not attempt to self-treat or stop current medications based on these preliminary findings.

This research is in the early discovery phase. Typically, it takes 10 to 15 years from basic research findings like these to develop a medication that reaches patients. The next steps would involve optimizing drugs that block NAT10, testing them in more animal models, and eventually conducting human clinical trials. Patients should expect that any new NAT10-targeting therapy would not be available for several years at minimum.

Frequently Asked Questions

What is aortic valve calcification and why does it happen?

Aortic valve calcification is the hardening of the heart valve due to calcium buildup, which restricts blood flow. This research shows that a protein called NAT10 triggers this process by activating PCSK9, causing valve cells to transform into bone-like tissue. High cholesterol and age are major risk factors.

Can NAT10 inhibitors treat aortic valve disease in humans?

NAT10 inhibitors show promise in mice and laboratory studies, but human clinical trials have not yet been conducted. These findings are preliminary, and it typically takes 10 to 15 years to develop medications from basic research to patient availability. Patients should continue current treatments while researchers develop new therapies.

How does NAT10 cause valve cells to calcify?

NAT10 modifies the PCSK9 gene’s messenger RNA through a process called ac4C acetylation, making the message more stable so more PCSK9 protein is produced. This PCSK9 protein then triggers valve cells to undergo osteogenic differentiation, transforming them into bone-like tissue that hardens the valve.

Should I get tested for NAT10 levels if I have valve disease?

Current clinical practice does not include NAT10 testing. This research suggests that measuring NAT10 levels might eventually help assess disease severity, but this application is not yet available. Continue working with your cardiologist using established diagnostic methods like echocardiograms.

What can I do now to prevent aortic valve calcification?

Manage risk factors by maintaining healthy cholesterol levels, controlling blood pressure, exercising regularly, and eating a heart-healthy diet. If you have valve disease, attend regular cardiology appointments for monitoring. This research may lead to new preventive treatments in the future, but current prevention focuses on managing cardiovascular risk factors.

Want to Apply This Research?

  • Users with aortic valve disease could track their cardiovascular health markers including blood pressure readings, cholesterol levels, and any symptoms like shortness of breath or chest discomfort. Recording these metrics weekly would help identify trends and provide data to share with their cardiologist.
  • Users should focus on cholesterol management through diet and exercise, as high cholesterol appears to accelerate valve calcification. The app could help users track heart-healthy foods, monitor daily steps, and log cholesterol-lowering activities. Users could also set reminders for regular cardiology appointments to monitor valve function.
  • Establish a long-term tracking system that records blood pressure, cholesterol levels, and any cardiac symptoms monthly. Users should note any changes in exercise tolerance or new symptoms and share this data with their healthcare provider. As new NAT10-targeting therapies become available, users can track their response to treatment using the same metrics.

This article summarizes research findings about aortic valve calcification and NAT10 protein. The findings are based on laboratory and animal studies and have not yet been tested in human clinical trials. This information is for educational purposes only and should not be used to diagnose, treat, or prevent any disease. If you have aortic valve disease or concerns about your heart health, consult with a qualified cardiologist or healthcare provider. Do not stop or change any current medications or treatments based on this research. Any new therapies targeting NAT10 are not yet available for human use.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: NAT10 exacerbates aortic valve calcification via PCSK9 mRNA ac4C acetylation. , iScience (2026). PubMed 42909140 | DOI
Topics
aortic valve calcification NAT10 protein PCSK9 heart valve disease ac4C acetylation calcific aortic valve disease valve hardening cardiovascular health